Duineveld, Caroline
Steenbergen, Eric J.
Bomback, Andrew S.
van de Kar, Nicole C. A. J.
Wetzels, Jack F. M.
Funding for this research was provided by:
Radboud University Medical Center
Article History
Received: 5 March 2020
Revised: 30 April 2020
Accepted: 4 May 2020
First Online: 23 May 2020
Compliance with ethical standards
:
: The results presented in this paper have not been published previously in whole or part. N.C.A.J.K. and J.F.M.W. are members of the Alexion Scientific Advisory Board of aHUS and received consultation and speaker’s fees. A.S.B. has received consulting fees from Achillion, ChemoCentryx, and Novartis. All pharmaceutical companies had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. C.D., N.C.A.J.K., and J.F.M.W. participate in clinical trials for complement-mediated disease funded by ChemoCentryx and Achillion. The authors declare that they have no other relevant financial interests.
: This case series involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. According to the Dutch law, no approval from the ethical medical committee was necessary.
: Informed consent was obtained from both participants included in the study.
: The participants signed informed consent regarding publishing their data and images of the kidney biopsies.